Selectively targeting mutant BRAF in thyroid cancer.
Ball
Douglas W
DW
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002291:Carcinoma, Papillary / Q000188:drug therapy*; D016503:Drug Delivery Systems; D006801:Humans; D051379:Mice; D050505:Mutant Proteins / Q000037:antagonists & inhibitors; D020125:Mutation, Missense / Q000502:physiology; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*; D013379:Substrate Specificity; D013964:Thyroid Neoplasms / Q000188:drug therapy*; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D050505:Mutant Proteins; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf